IBRN vs PBE
iShares Neuroscience and Healthcare ETF against Invesco Biotechnology & Genome ETF: cost, size, returns, what they hold and how much of it is the same.
Overlap by weight
14%
5 shared positions
Fee gap
11 bp
IBRN is cheaper
1-year return gap
21.2 pts
PBE is ahead
Larger fund
PBE
$422M
Side by side
| IBRN | PBE | |
|---|---|---|
| Fund | iShares Neuroscience and Healthcare ETF | Invesco Biotechnology & Genome ETF |
| Issuer | iShares | Invesco |
| Category | Biotech & Health Innovation | Biotech & Health Innovation |
| Expense ratio | 0.47% | 0.58% |
| Assets | $6.4M | $422M |
| Average daily dollar volume | $82K | $1.7M |
| Listed | Aug 24, 2022 | Jun 23, 2005 |
| FrenzyCap score | 37 | 49 |
| 1-month return | −14.9% | +4.2% |
| 3-month return | −16.9% | +7.0% |
| Year to date | −1.8% | +17.9% |
| 1-year return | +13.3% | +34.5% |
| 30-day volatility | 22.0% | 22.6% |
| Worst drawdown, 1 year | −22.8% | −11.8% |
| Trailing 12-month yield | 1.01% | 1.38% |
| Holdings | 81 | 33 |
| Top 10 weight | 41.1% | 48.4% |
| Look-through P/E | — | 106.3 |
| Holdings vs fair value | +12.7% | +8.1% |
| Holdings above 200-day average | 33% | 78% |
| Net flow, latest 3 reported months | $0 thru Jul 2026 | +$5.9M thru Jul 2026 |
| 30-day implied volatility | 35.9% | 25.9% |
| Holdings as of | as of Oct 8, 2026issuer data | as of Oct 8, 2026issuer data |
Returns are price returns and exclude distributions. Flows are each fund's own latest reported months and may not cover the same period.
Largest shared holdings
20% of IBRN · 15% of PBE
Sector mix of the stock holdings
| Sector | IBRN | PBE | Gap |
|---|---|---|---|
| Health Care | 80.0% | 91.3% | −11.2% |
| Technology | 0.0% | 6.2% | −6.2% |
| Materials | 2.4% | 0.0% | +2.4% |
More: full overlap table · IBRN holdings · PBE holdings
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.